March 1, 2021 07:47 AM ESTUpdated 08:40 AM
Deals
China
Pharma

An­gling Pfiz­er, As­traZeneca jumps in­to com­mer­cial PD-(L)1 fight in Chi­na

Amber Tong

Is a Big Phar­ma com­mer­cial show­down brew­ing in Chi­na’s PD-(L)1 mar­ket?

Months af­ter Pfiz­er out­lined a sprawl­ing $200 mil­lion pact with CStone part­ly to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

IGM Bio­sciences’ au­toim­mune piv­ot lasts three months af­ter in­ter­im da­ta dis­ap­point

Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Bay­er says elin­zane­tant quelled hot flash­es in women un­der­go­ing can­cer treat­ment

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Ten­point re­veals pos­i­tive Phase 3 da­ta for vi­sion drug af­ter Vi­s­us merg­er

A service from the Financial Times